Tumor treating induced fields: a new treatment option for patients with glioblastoma

被引:0
|
作者
Cai, Zehao [1 ]
Yang, Zukai [2 ]
Wang, Ying [2 ]
Li, Ye [3 ]
Zhao, Hong [3 ]
Zhao, Hanwen [4 ]
Yang, Xue [1 ]
Wang, Can [1 ]
Meng, Tengteng [3 ]
Tong, Xiao [2 ]
Zheng, Hao [2 ]
He, Zhaoyong [2 ]
Niu, Chunli [3 ]
Yang, Junzhi [3 ]
Chen, Feng [1 ]
Yang, Zhi [5 ]
Zou, Zhige [4 ]
Li, Wenbin [1 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurooncol, Canc Ctr, Beijing, Peoples R China
[2] Capital Med Univ, Sch Basic Med Sci, Beijing, Peoples R China
[3] Kunlun Tripot Beijing Med Technol Co Ltd, Beijing, Peoples R China
[4] Huazhong Univ Sci & Technol, Sch Integrated Circuits, Wuhan, Hubei, Peoples R China
[5] Capital Med Univ, Sch Biomed Engn, Beijing, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
关键词
electromagnetic therapy; glioblastoma; central nervous system; electromagnetic induction; transformer; NEWLY-DIAGNOSED GLIOBLASTOMA; ELECTROMAGNETIC-FIELDS; CELL-PROLIFERATION; 100; HZ; CANCER; TRIAL; CHEMOTHERAPY; TEMOZOLOMIDE; METASTASES; CARCINOMA;
D O I
10.3389/fneur.2024.1413236
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Currently, a range of electromagnetic therapies, including magnetic field therapy, micro-currents therapy, and tumor treating fields, are under investigation for their potential in central nervous system tumor research. Each of these electromagnetic therapies possesses distinct effects and limitations. Our focus is on overcoming these limitations by developing a novel electric field generator. This generator operates by producing alternating induced currents within the tumor area through electromagnetic induction.Methods Finite element analysis was employed to calculate the distribution of electric fields. Cell viability was assessed using the CCK-8 assay. Tumor volumes and weights served as indicators to evaluate the effectiveness of TTIF. The in-vivo imaging system was utilized to confirm tumor growth in the brains of mice.Results TTIF significantly inhibited the proliferation of U87 cells both in vitro and in vivo.Conclusion TTIF significantly inhibited the proliferation of U87 cells both in vitro and in vivo. Consequently, TTIF emerges as a potential treatment option for patients with progressive or metastatic GBM.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Tumor treating fields increases membrane permeability in glioblastoma cells
    Chang, Edwin
    Patel, Chirag B.
    Pohling, Christoph
    Young, Caroline
    Song, Jonathan
    Flores, Thomas Anthony
    Zeng, Yitian
    Joubert, Lydia-Marie
    Arami, Hamed
    Natarajan, Arutselvan
    Sinclair, Robert
    Gambhir, Sanjiv S.
    CELL DEATH DISCOVERY, 2018, 4
  • [22] Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma
    Hayes, Michael J.
    Prasad, Vinay
    JOURNAL OF CANCER POLICY, 2019, 21
  • [23] Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
    Fishman, Hila
    Monin, Roni
    Dor-On, Eyal
    Kinzel, Adrian
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) : 83 - 94
  • [24] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
    Toms, S. A.
    Kim, C. Y.
    Nicholas, G.
    Ram, Z.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 141 (02) : 467 - 473
  • [25] Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study
    Kanamori, Masayuki
    Tsuzuki, Shunsuke
    Shibahara, Ichiyo
    Saito, Kuniaki
    Shimoda, Yoshiteru
    Tanaka, Kazuhiro
    Yamaguchi, Shigeru
    Natsumeda, Manabu
    Matsutani, Tomoo
    Hanihara, Mitsuto
    Nakada, Mitsutoshi
    Kuroda, Jun-Ichiro
    Matsuda, Masahide
    Yoshimoto, Koji
    Yonezawa, Ushio
    Sonoda, Yukihiko
    Takano, Koji
    Yonezawa, Hajime
    Otani, Yoshihiro
    Nakahara, Yukiko
    Uchida, Masashi
    Nonaka, Masahiro
    Mineharu, Yohei
    Kitamura, Yohei
    Yamashita, Shinji
    Yamauchi, Takahiro
    Miyake, Yohei
    Deguchi, Shoichi
    Beppu, Takaaki
    Tamura, Kaoru
    Koizumi, Shinichiro
    Hirose, Yuichi
    Asano, Kenichiro
    Hiruta, Ryo
    Kinoshita, Manabu
    Miyake, Keisuke
    Nakayama, Noriyuki
    Inoue, Akihiro
    Ono, Takahiro
    Sasaki, Takahiro
    Akiyama, Yukinori
    Fukami, Shinjiro
    Yoshino, Atsuo
    Kawanishi, Yu
    Asanome, Taku
    Yamaguchi, Takuhiro
    Takahashi, Masamichi
    Yamasaki, Fumiyuki
    Arakawa, Yoshiki
    Narita, Yoshitaka
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [26] Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
    Robins, H. Ian
    Nguyen, HuyTram N.
    Field, Aaron
    Howard, Steven
    Salamat, Shahriar
    Deming, Dustin A.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [27] Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy
    Saria, Marlon Garzo
    Kesari, Santosh
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2016, 20 (05) : 9 - 13
  • [28] Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune® System
    Kinzel, Adrian
    Ambrogi, Michael
    Varshaver, Michael
    Kirson, Eilon D.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [29] The Value of Tumor Treating Fields in Glioblastoma
    Zhang, Chaochao
    Du, Jianyang
    Xu, Weidong
    Huang, Haiyan
    Gao, Li
    JOURNAL OF KOREAN NEUROSURGICAL SOCIETY, 2020, 63 (06) : 681 - 688
  • [30] Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors
    Wang, Junjie
    Du, Quan
    Chen, Jiarui
    Liu, Jianjian
    Gu, Zhaowen
    Wang, Xiaoyu
    Zhang, Anke
    Gao, Shiqi
    Shao, Anwen
    Zhang, Jianmin
    Wang, Yongjie
    FRONTIERS IN ONCOLOGY, 2024, 14